FULGENT GENETICS, INC. Deferred State and Local Income Tax Expense (Benefit)
FULGENT GENETICS, INC. (FLGT) reported Deferred State and Local Income Tax Expense (Benefit) of $197.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit · last filed 2026-02-27
- FULGENT GENETICS, INC. deferred state and local income tax expense (benefit) for fiscal 2025 was $197.00K.
- FULGENT GENETICS, INC. deferred state and local income tax expense (benefit) for fiscal 2024 was -$734.00K, a 117.90% decline from fiscal 2023.
- FULGENT GENETICS, INC. deferred state and local income tax expense (benefit) for fiscal 2023 was $4.10M.
- FULGENT GENETICS, INC. deferred state and local income tax expense (benefit) for fiscal 2022 was -$4.52M.
| Period end | Deferred State and Local Income Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | $197.00K 10-K · filed 2026-02-27 |
| 2024-12-31 | -$734.00K 10-K · filed 2026-02-27 |
| 2023-12-31 | $4.10M 10-K · filed 2026-02-27 |
| 2022-12-31 | -$4.52M 10-K · filed 2025-02-28 |
| 2021-12-31 | -$717.00K 10-K · filed 2024-02-28 |
| 2020-12-31 | -$14.00K 10-K · filed 2023-02-28 |
| 2019-12-31 | -$280.00K 10-K · filed 2022-02-28 |
| 2018-12-31 | -$308.00K 10-K · filed 2020-03-13 |
| 2017-12-31 | -$36.00K 10-K · filed 2019-03-22 |
| 2016-12-31 | -$49.00K 10-K · filed 2018-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B |